The Canadian Cooperative Study of Platelet Suppressant Therapy in Threatened Stroke

• References

• 1 Anturane Reinfarction Trial Research Group. 1978; Sulfinpyrazone in the prevention of cardiac death after myocardial infarction. New England Journal of Medicine 298: 289.
• 2 Barnett H.J.M.. 1974; Transient cerebral ischemia: pathogenesis, prognosis and management. Annual Meeting of the Royal College of Physicians and Surgeons of Canada 7: 153.
• 3 Blakely J.A., and Gent M.. 1975. Platelets, drugs and longevity in a geriatric population. In: Hirsh J., Cade J.F., Gallus A.S., and Schonbaum E.. (eds.) Platelets, Drugs and Thrombosis. Karger; Basel.:
• 4 Canadian Cooperative Study Group. 1978; A randomized trial of aspirin and sulfinpyrazone in threatened stroke. New England Journal of Medicine 299: 53.
• 5 Evans G.. 1972; Effect of drugs that suppress platelet surface interaction on the incidence of amaurosis fugax and transient cerebral ischemia. Surgical Forum 23: 239.
• 6 Fields W.S., Lemak N. A., Frankowski R.F., and Hardy R.J.. 1977; Controlled trial of aspirin in cerebral ischemia. Stroke 8: 301.
• 7 Fisher C.M.. 1959; Observations of the fundus oculi in transient monocular blindness. Neurology 9: 333.
• 8 Gent M., and Sackett D.L.. 1979; The qualification and disqualification of patients and events in long-term cardiovascular clinical trials. Thrombosis and Haemostasis 40: 123.
• 9 Harris W.H., Salzman E.W., Athanasoulis C.A., Waltman A.C., and Desanctis R.W.. 1977; Aspirin prophylaxis of venous thromboembolism after total hip replacement. New England Journal of Medicine 297: 1246.
• 10 Harrison M.J.G., Marshall J., Meadows J.C., and Russell R.W.R.. 1971; Effect of aspirin in amaurosis fugax. Lancet 2: 743.
• 11 Hirsh J., Blajchman M., and Kaegi A.. 1978. The bleeding time. In: Day J., Holmsen H., and Zucker M.. (eds.) Platelet Function Testing. D.H.E.W. Publication, No. (NIH) 78-1087; Washington D.C.:
• 12 Kaegi A., Pineo G.F., Shimizu A., Trivedi H., Hirsh J., and Gent M.. 1975; The role of sulfinpyrazone in the prevention of arteriovenous shunt thrombosis. Circulation 52: 497.
• 13 Kelton J.G., Carter C., Buchanan M., and Hirsh J.. 1978; Thrombogenic effect of high dose aspirin in injury-induced experimental venous thrombosis. Clinical Research 26: 350A.
• 14 Millikan C.H.. 1970; Anticoagulant therapy in cerebrovacular disease. Cerebrovascular Survey Report. National Institute of Neurological Diseases and Stroke 218.
• 15 Mundall J., Quintero P., von Kaulla K.N., Harmon R., and Austin J.. 1972; Transient monocular blindness and increased platelet aggregability treated with aspirin: a case report. Neurology 22: 280.
• 16 Peto R., Pike M.C., Armitage P., Breslow N.E., Cox D.R., Howard S.V., Mantel N., McPherson K., Peto J., and Smith P.G.. 1977; Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. British Journal of Cancer 35: 1.
• 17 Smythe H.A., Orygzlo M.A., Murphy E.A., and Mustard J.F.. 1965; The effect of sulfinpyrazone (Anturan) on platelet economy and blood coagulation in man. Canadian Medical Association Journal 92: 818.
• 18 Warren B.A., and Vales O.. 1975; Electron microscopy of the sequence of events in the atheroembolic occlusion of cerebral arteries in an animal model. British Journal of Experimental Pathology 56: 205.
• 19 Weiss H.J., and Aledort L.M.. 1967; Impaired platelet/corrective-tissue reaction in man after aspirin ingestion. Lancet 2: 495.